Avibactam

CHEMBL1689063 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

265.2 g/mol

LogP

-1.8

Phase

4

A beta-lactamase inhibitor that inactivates enzymes produced by resistant bacteria that would otherwise destroy cephalosporin and other beta-lactam antibiotics. It is always used in combination with a partner antibiotic to restore activity against carbapenem-resistant organisms.

Berat Molekul

265,2500 g/mol

LogP

-1,80

TPSA

139,00 Å²

Lipinski RO5

Lulus

Area Terapeutik

Infectious Disease

Mekanisme Kerja

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O

InChI

InChI=1S/C7H11N3O6S/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15/h4-5H,1-3H2,(H2,8,11)(H,13,14,15)/t4-,5+/m1/s1

Molecular Formula

C7H11N3O6S

HBD / HBA

2 / 6

Ikatan yang Dapat Dirotasi

3

Atom Berat

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A beta-lactamase inhibitor that inactivates enzymes produced by resistant bacteria that would otherwise destroy cephalosporin and other beta-lactam antibiotics. It is always used in combination with a partner antibiotic to restore activity against carbapenem-resistant organisms.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Avibactam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1689063. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 9835049. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Mencari informasi yang ramah bagi pasien?

Avibactam di PillFYI

Struktur

Data Cepat

Rumus: C7H11N3O6S
Sinonim: 2

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.